NextCell Pharma Investor Relations Material

NextCell Pharma AB is a Swedish biopharmaceutical company specializing in the development of novel stromal cell therapies, primarily focusing on treatments for autoimmune and inflammatory diseases. Its flagship product, ProTrans, targets type 1 diabetes. The company also operates Cellaviva, the largest private stem cell bank in Scandinavia, which stores and processes stem cells from umbilical cords. NextCell Pharma integrates both therapeutic development and biobanking services within its operations. The company is headquartered in Huddinge, Sweden, and its shares are listed on the Nasdaq Stockholm.